logo
Google Reviews Logo

317.636.6481

One Indiana Square, Suite 1400 Indianapolis, Indiana 46204

Make a Payment
logo
CONTACT US
CALL US
  • Home
  • Firm Overview
  • Our Attorneys
  • Practice Areas
    • Pharmaceutical Drug & Medical Device Litigation
    • Personal Injury
    • Sexual Abuse
    • Class Action
    • Medical Malpractice
    • Eminent Domain
    • Family Law
    • Business Services, Real Estate & Business Litigation
    • Bankruptcy, Creditor’s Rights, & Commercial & Business Law
    • Appellate Law
  • Firm News
    • News & Announcements
    • Alerts
  • Resources
    • Video Library
    • Blog
  • Contact Us
Google Reviews Logo

317.636.6481

One Indiana Square, Suite 1400 Indianapolis, Indiana 46204

Make a Payment
  • Home
  • Firm Overview
  • Our Attorneys
  • Practice Areas
    • Pharmaceutical Drug & Medical Device Litigation
    • Personal Injury
    • Sexual Abuse
    • Class Action
    • Medical Malpractice
    • Eminent Domain
    • Family Law
    • Business Services, Real Estate & Business Litigation
    • Bankruptcy, Creditor’s Rights, & Commercial & Business Law
    • Appellate Law
  • Firm News
    • News & Announcements
    • Alerts
  • Resources
    • Video Library
    • Blog
  • Contact Us

Home » FDA Advisory Committee Recommends Label Change for Fluoroquinolone Antibiotics

FDA Advisory Committee Recommends Label Change for Fluoroquinolone Antibiotics

The U.S. Food and Drug Administration met November 5, 2015, to discuss the risks and benefits of using fluoroquinolones on patients with bronchitis, sinusitis, and urinary tract infections. Fluoroquinolone drugs are a powerful class of antibiotic drugs and include brand names Cipro, Levaquin, and Avelox.

Fluoroquinolone antibiotics have been linked to a list of serious side effects. The FDA cited adverse event reporting from patients highlighting a “constellation of symptoms” that is referred to as Fluoroquinolone-Associated Disability, or FQAD. People may have FQAD are described as:

  • Patients who experience two or more adverse events in two or more body systems including peripheral neuropathy, neuropsychiatric, musculoskeletal, senses, cardiovascular, and skin.
  • Patients who were previously healthy.
  • Patients who took fluoroquinolone to treat urinary tract infections, bronchitis, or sinusitis.
  • Patients who had a substantial disruption of their normal life functions.

Peripheral neuropathy is a type of damage to the central nervous system and can make a patient experience severe pain, difficulty moving, and problems with involuntary functions like breathing, digestion, and circulation. Peripheral neuropathy causes weakness, numbness, tingling, burning, and other sensations of pain often in the hands, arms, legs, and feet.

Media reports have highlighted stories of formerly healthy patients who took fluoroquinolone drugs like Cipro and Levaquin and developed severe nerve damage causing life-changing injuries. FDA concerns about the safety of fluoroquinolone drugs increased after a review of a large number of adverse event reports.

FDA Says Label Change Needed

FDA review panel members from the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted overwhelmingly that the benefits and risks for fluoroquinolone antibacterial drugs support a need for a label change. The FDA will review the findings of this panel and decide whether or not a black box or other safety communication should be added to the labels of fluoroquinolone drugs like Levaquin and Cipro.

Levaquin Lawsuits

Thousands of lawsuits have been filed in state and federal courts across the United Stated by patients who experienced severe nerve damage and other serious injuries after taking quinolone-containing antibiotics Levaquin, Cipro, and Avelox. If you or someone you know has taken these drugs and experienced severe nerve damage, our product liability attorneys can help. Cohen & Malad, LLP has been litigating serious personal injury claims against large drug manufacturers for many years and can help you get the compensation you deserve.

One Indiana Square Suite 1400
Indianapolis, Indiana 46204

Copyright ©  Cohen & Malad, LLP. All rights reserved.

Disclaimer  |  Privacy Policy

 

Schedule a free consultation Today
  • This field is for validation purposes and should be left unchanged.

Schedule a free consultation Today

  • This field is for validation purposes and should be left unchanged.

ALERTS

University of Southern California Agrees to $852 Million Settlement in Sexual Abuse Lawsuit

More than 700 women who claim University of Southern California campus gynecologist Dr. George Tyndall sexually abused .. Read More

SEE ALL ALERTS

In the News

Natalie A. Lyons Joins Class Action Practice at Cohen & Malad, LLP Six Cohen & Malad, LLP Attorneys Named to 2021 Indiana Super Lawyers Rising Stars List Thirteen Cohen & Malad, LLP Attorneys Named to 2021 Indiana Super Lawyers List
READ OUR NEWS